Abstract
Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, α8 integrin. HC11 cells derived from normal mammary epithelium do not express α8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express α8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-β1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38MAPK and JNK signaling pathways. Since preinflammatory cytokines also act through p38MAPK and JNK signaling pathways, the possible role of TNF-α in tenascin-W expression was also examined. TNF-α induced the expression of both tenascin-W and tenascin-C, and this induction was p38MAPK- and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams M, Jones JL, Walker RA, Pringle JH and Bell SC . (2002). Cancer Res., 62, 3289–3297.
Andres AC, Schonenberger CA, Groner B, Hennighausen L, LeMeur M and Gerlinger P . (1987). Proc. Natl. Acad. Sci. USA, 84, 1299–1303.
Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, LeMeur M, Gerlinger P and Groner B . (1988). Genes Dev., 2, 1486–1495.
Chen J, Baskerville C, Han Q, Pan ZK and Huang S . (2001). J. Biol. Chem., 276, 47901–47905.
Chiquet-Ehrismann R . (2004). Int. J. Biochem. Cell Biol., 36, 986–990.
Chiquet-Ehrismann R and Chiquet M . (2003). J. Pathol., 200, 488–499.
Chiquet-Ehrismann R and Tucker RP . (2004). Int. J. Biochem. Cell Biol., 36, 1085–1089.
Clement JH, Sanger J and Hoffken K . (1999). Int. J. Cancer, 80, 250–256.
Fischer D, Tucker RP, Chiquet-Ehrismann R and Adams JC . (1997). Mol. Biol. Cell, 8, 2055–2075.
Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R and Roman-Roman S . (2001). Bone, 28, 491–498.
Geffrotin C, Horak V, Crechet F, Tricaud Y, Lethias C, Vincent-Naulleau S and Vielh P . (2000). Biochim. Biophys. Acta, 1524, 196–202.
Goepel C, Buchmann J, Schultka R and Koelbl H . (2000). Gynecol. Oncol., 79, 372–378.
Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G and Caverzasio J . (2003). J. Bone Mineral Res., 18, 2060–2068.
Hasegawa K, Yoshida T, Matsumoto K, Katsuta K, Waga S and Sakakura T . (1997). Acta Neuropathol., 93, 431–437.
Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A and Orend G . (2001). Cancer Res., 61, 8586–8594.
Hynes NE, Taverna D, Harwerth IM, Ciardiello F, Salomon DS, Yamamoto T and Groner B . (1990). Mol. Cell Biol., 10, 4027–4034.
Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ and Pavlidis N . (2002). Eur. J. Cancer, 38, 2362–2370.
Jones FS and Jones PL . (2000). Dev. Dyn., 218, 235–259.
Kaya H, Hucumenoglu S, Bozkurt SU, Ekicioglu G and Kotiloglu E . (2002). Eur. J. Gynaecol. Oncol., 23, 261–263.
Latijnhouwers MA, Pfundt R, de Jong GJ and Schalwijk J . (1998). Matrix Biol., 17, 305–316.
Lemonnier J, Ghayor C, Guicheux J and Caverzasio J . (2004). J. Biol. Chem., 279, 259–264.
Li F, Strange R, Friis RR, Djonov V, Altermatt HJ, Saurer S, Niemann H and Andres AC . (1994). Int. J. Cancer, 59, 560–568.
Liu LX, Jiang HC, Liu ZH, Zhou J, Zhang WH, Zhu AL, Wang XQ and Wu M . (2002). World J. Gastroenterol., 8, 631–637.
Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y and Sakakura T . (1987). Proc. Natl. Acad. Sci. USA, 84, 4621–4625.
Malik ST, Naylor MS, East N, Oliff A and Balkwill FR . (1990). Eur. J. Cancer, 26, 1031–1034.
Michalaki V, Syrigos K, Charles P and Waxman J . (2004). Br. J. Cancer, 90, 2312–2316.
Munarini N, Jager R, Abderhalden S, Zuercher G, Rohrbach V, Loercher S, Pfanner-Meyer B, Andres AC and Ziemiecki A . (2002). J. Cell Sci., 115, 25–37.
Neidhardt J, Fehr S, Kutsche M, Lohler J and Schachner M . (2003). Mol. Cell Neurosci., 23, 193–209.
Nikolova Z, Djonov V, Zuercher G, Andres AC and Ziemiecki A . (1998). J. Cell Sci., 111, 2741–2751.
Ocvirk J, Stabuc B, Rudolf Z, Galvani V and Curin-Serbec V . (2000). Melanoma Res., 10, 253–258.
Pouliot F, Blais A and Labrie C . (2003). Cancer Res., 63, 277–281.
Qin Z, Kruger-Krasagakes S, Kunzendorf U, Hock H, Diamantstein T and Blankenstein T . (1993). J. Exp. Med., 178, 355–360.
Salh B, Marotta A, Wagey R, Sayed M and Pelech S . (2002). Int. J. Cancer, 98, 148–154.
Scherberich A, Tucker RP, Samandari E, Brown-Luedi M, Martin D and Chiquet-Ehrismann R . (2004). J. Cell Sci., 17, 571–581.
Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D and Pytela R . (1998). J. Biol. Chem., 270, 23196–23202.
Schoenenberger CA, Andres AC, Groner B, van der Valk M, LeMeur M and Gerlinger P . (1988). EMBO J., 7, 169–175.
Schultz RM . (2003). Prog. Drug Res., 60, 59–92.
Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K and Clement JH . (2003). Int. J. Oncol., 23, 89–95.
Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y and Yoshida T . (2003). Am. J. Pathol., 162, 1857–1867.
Vinals F, Lopez-Rovira T, Rosa JL and Ventura F . (2002). FEBS Lett., 510, 99–104.
Weber P, Montag D, Schachner M and Bernhardt RR . (1998). J. Neurobiol., 35, 1–16.
Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE and Yu D . (2001). Cancer Res., 61, 1727–1732.
Zweers MC, van Vlijmen-Willems IM, van Kuppevelt TH, Mecham RP, Steijlen PM, Bristow J and Schalkwijk J . (2004). J. Invest. Dermatol., 122, 885–891.
Acknowledgements
This research was supported by grants from the Novartis Research Foundation and the Krebsliga beider Basel (A Scherberich) and the National Science Foundation (0235711; RP Tucker).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scherberich, A., Tucker, R., Degen, M. et al. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene 24, 1525–1532 (2005). https://doi.org/10.1038/sj.onc.1208342
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208342
Keywords
This article is cited by
-
The extracellular matrix in tumor progression and metastasis
Clinical & Experimental Metastasis (2019)
-
Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers
Nature Communications (2017)
-
The arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis
BMC Genomics (2012)
-
Expression of tenascin-C and its isoforms in the breast
Cancer and Metastasis Reviews (2010)